

Gladden-Sorensen, Christian

From: Berl, David
Sent: Friday, September 12, 2025 1:20 PM
To: Shannon Gibson
Cc: raynimrod@quinnemanuel.com; Eylea; grp-pw-eylea-biosimilars@paulweiss.com; regeneronpatent@lists.kellogghansen.com; fogel@fr.com; service-formycon_team@fr.com; rcerwinski@geminilaw.com; dg-ct-aflibercept@geminilaw.com; jlabbe@marshallip.com; mgb-amgen-abp938@marshallip.com; abp938@rothwellfigg.com; bpostal@rothwellfigg.com; jhynds@rothwellfigg.com; dg-aflibercept@goodwinlaw.com; Grammel, Molly; QE - Samsung Bioepis
Subject: RE: In re: Aflibercept Patent Litigation, MDL Case No. 1:24-md-03103-TSK-JPM

Dear Ms. Gibson:

I write as Liaison Counsel for Regeneron in the above-captioned proceeding, and in response to Mr. Nimrod's email of September 3, 2025, requesting an in-person status conference. As reflected in Mr. Nimrod's email, Regeneron did not believe holding a status conference on the same day as a hearing on Regeneron's motion for a preliminary injunction against Sandoz, due to the anticipated duration and complexity of such a hearing. The Sandoz hearing has been cancelled, and a hearing on Formycon's motion to dissolve the injunction against it has been scheduled in its place. That motion does not present the same complexity. Regeneron therefore joins Defendants Celltrion, Samsun Bioepis, and Formycon in requesting an in-person status conference be held the same day on September 29, 2025.

Best,

David I. Berl

Williams & Connolly LLP

680 Maine Avenue, S.W., Washington, DC 20024

(P) 202-434-5491 | (F) 202-434-5029

dberl@wc.com | www.wc.com

From: Ray Nimrod <raynimrod@quinnemanuel.com>
Sent: Wednesday, September 3, 2025 9:32 AM
To: Shannon Gibson <shannon_gibson@wvnd.uscourts.gov>
Cc: Berl, David <DBerl@wc.com>; Eylea <Eylea@wc.com>; grp-pw-eylea-biosimilars@paulweiss.com; regeneronpatent@lists.kellogghansen.com; fogel@fr.com; service-formycon_team@fr.com; rcerwinski@geminilaw.com; dg-ct-aflibercept@geminilaw.com; jlabbe@marshallip.com; mgb-amgen-abp938@marshallip.com; abp938@rothwellfigg.com; bpostal@rothwellfigg.com; jhynds@rothwellfigg.com; dg-aflibercept@goodwinlaw.com; Grammel, Molly <mgrammel@goodwinlaw.com>; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>
Subject: In re: Aflibercept Patent Litigation, MDL Case No. 1:24-md-03103-TSK-JPM

Re: *In re: Aflibercept Patent Litigation*, MDL Case No. 1:24-md-03103-TSK-JPM

Ms. Gibson:

I write as Liaison Counsel for Samsung Bioepis in the above-captioned MDL proceeding.

All parties to the MDL have previously requested that the Court schedule an in-person status conference for purposes of setting a case schedule for further proceedings. (See Mr. Berl's April 30, 2025 Email.) I write today to renew that

request with a specific proposal to hold the status conference the same day as the Sandoz preliminary injunction hearing currently scheduled for September 29, 2025.

Defendants Celltrion and Formycon join in this request.

Plaintiff Regeneron and Defendant Sandoz have stated that they do not believe that the status conference should be held on the same day as the Sandoz PI hearing but are amenable to a status conference at the Court's convenience.

Defendant Amgen is also amenable to a status conference at the Court's convenience.

I have copied counsel for all parties to the MDL on this email.

Respectfully submitted,

Ray Nimrod

Partner, Co-Chair of Global Life Sciences Practice

Quinn Emanuel Urquhart & Sullivan LLP.

+1-347-920-7055 Mobile

raynimrod@quinnemanuel.com

www.quinnemanuel.com

NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.